Botanical

Pygeum

Prunus africana

Evidence TierDWADA NOT PROHIBITED

tuneTypical Dose

Usually 100 to 200 mg/day of bark extract in the older BPH literature

watchEffect Window

Symptom changes in BPH literature usually emerge over weeks rather than days.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Pygeum may modestly improve urinary symptoms from benign prostatic enlargement, but the evidence base is old, short, and much weaker than modern BPH treatment evidence.

Pygeum is one of the older prostate supplements with a real symptom signal in the literature, especially for nocturia and lower urinary tract symptoms linked to benign prostatic enlargement. The catch is that most of the evidence is dated and comes from short, lower-quality trials. That means pygeum can be framed as a low-confidence adjunctive option for urinary symptoms, but not as a dependable substitute for proper BPH evaluation or treatment.

Pygeum is usually framed around phytosterols and other bark-derived constituents that may affect prostatic inflammation, bladder contractility, or growth signaling. The mechanism remains less important than the clinical reality that the useful human evidence is limited to symptom changes in older BPH trials.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Possible reduction in nocturia
  • Possible improvement in lower urinary tract symptoms related to BPH

Secondary Outcomes

  • Possible improvement in peak urinary flow
  • Possible reduction in post-void residual volume

Safety

Contraindications and Interactions

Contraindications

  • Unexplained urinary retention, hematuria, or rapidly worsening urinary symptoms
  • Pregnancy
  • Lactation

Side effects

  • Mild GI upset
  • Nausea

Interactions

No entries provided

Avoid if

  • You are using it instead of proper evaluation for urinary symptoms
  • You have alarm urinary symptoms

Evidence

Study-level References

py-SRC-001Systematic review
Sourceopen_in_new

Wilt T, Ishani A, MacDonald R. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044. doi:10.1002/14651858.CD001044. PMID:11869585.

Population: Men with symptomatic benign prostatic hyperplasia enrolled in randomized trials of Pygeum africanum.

Dose protocol: Usually 100 to 200 mg/day across older pygeum bark-extract trials

Key findings: Improved overall symptoms, nocturia, urinary flow, and residual urine versus placebo.

Notes: Main evidence anchor, but dated and methodologically limited.

Paper content

This classic Cochrane review is still the main evidence anchor for pygeum. It found that pygeum improved overall urinary symptoms, nocturia, peak urinary flow, and residual urine versus placebo in men with BPH-type symptoms. The major limitation is that the evidence base is old, short, and methodologically weak by current standards, so pygeum deserves low-confidence symptom-relief framing rather than strong modern endorsement.

py-SRC-002Overview of systematic reviews
Sourceopen_in_new

Tacklind J, MacDonald R, Rutks I, et al. Dietary supplements for benign prostatic hyperplasia. An overview of systematic reviews. Maturitas. 2012;73(4):286-291. doi:10.3109/13880209.2012.707347. PMID:22883375.

Population: Men with benign prostatic hyperplasia or lower urinary tract symptoms across supplement-related systematic reviews.

Dose protocol: Review-level comparison of BPH dietary supplements

Key findings: Confirms that pygeum has some supportive symptom evidence, but not enough for strong confidence.

Notes: Useful context source rather than a primary efficacy trial.

Paper content

This overview is useful because it places pygeum in context next to other BPH supplements. It acknowledges a positive symptom signal for pygeum while also making clear that the evidence is much thinner and older than modern drug-trial standards. That supports a low-confidence adjunctive role rather than strong recommendation.

py-SRC-003Narrative review of in vitro, in vivo, and clinical trial evidence.
Sourceopen_in_new

Salinas-Casado J, Esteban-Fuertes M, Carballido-Rodriguez J, Cozar-Olmo JM. Review of the experience and evidence of Pygeum africanum in urological practice. Actas Urol Esp (Engl Ed). 2020;44(1):9-13. doi:10.1016/j.acuro.2019.08.002. PMID:31627963.

Population: Men with lower urinary tract symptoms related to benign prostatic hyperplasia (across reviewed studies).

Dose protocol: Narrative review of in vitro, in vivo, and clinical evidence for pygeum in urology.

Key findings: Confirms pygeum as a plausible option in the urological therapeutic arsenal, with modest clinical evidence for LUTS improvement.

Notes: Modern urologist-authored review that updates clinical context, though evidence level remains IV.

Paper content

This 2020 review by urologists examined the clinical and preclinical evidence for Pygeum africanum in BPH management. The review acknowledges in vitro and in vivo anti-inflammatory and anti-proliferative mechanisms, and summarizes existing clinical trial evidence supporting modest LUTS symptom improvement. The authors conclude that pygeum can be considered an option in the urological therapeutic arsenal but note the evidence level remains limited (level IV). This review provides useful modern clinical context for pygeum, though it does not add new primary trial data.

Guides

Setup

Help